TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Operable colon cancer amenable to curative surgery.~* Performance status of 0 to 1~* Informed consent form~* Patients must be at least 18 years of age.~Main Exclusion Criteria:~* Any concurrent other anti-tumor therapy~* Any prohibited concomitant medication within 30 days of surgery~* Pregnancy or breast-feeding.~* Second primary malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levoleucovorin 200 mg/m2 (Type: ACTIVE_COMPARATOR): One i.v. bolus injection of study drug after the patient has been anaesthetized.
- Levoleucovorin 60 mg/m2 (Type: ACTIVE_COMPARATOR): One i.v. bolus injection of study drug after the patient has been anaesthetized.
- 6R-MTHF 200 mg/m2 (Type: EXPERIMENTAL): One i.v. bolus injection of study drug after the patient has been anaesthetized.
- 6R-MTHF 60 mg/m2 (Type: EXPERIMENTAL): One i.v. bolus injection of study drug after the patient has been anaesthetized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Spices on Mixed Vegetable Intake Including Brassica Vegetables

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 30-60 years of age at screen.~2. BMI \>25 and \<30~3. In good health~4. Eat \<3 serving of vegetable per day.~c. Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.~-~Exclusion Criteria:~1. Any history of gastrointestinal disease except for appendectomy~2. Any subject with a history of diabetes mellitus, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP\>160mmHg, diastolic BP\>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.~3. Any subject allergic to spice or vegetables~4. Any subject who currently uses tobacco products.~5. Any subject who participates in vigorous physical activity on a regular basis.~6. Any subject who is unable or unwilling to comply with the study protocol.~   -

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Vegetable Intake with Spices Added (Type: EXPERIMENTAL): Subjects consuming vegetables with mixed-spices added.
- Vegetable Intake without Spices Added (Type: ACTIVE_COMPARATOR): Subjects consuming vegetables without spice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Has a diagnosis of Type 2 Diabetes Mellitus (T2DM)~* Has HbA1c of 7.5% to 12.0%, inclusive, at Visit 1 (Screening).~* Has fasting plasma glucose (FPG) concentration \<280 mg/dL (15.6 mmol/L) at Visit 1 (Screening)~* Treated with basal insulin glargine at a dose of ≥20 units/day once daily for at least 6 weeks prior to Screening, in combination with diet and exercise alone or in combination with:~  1. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1~ 2. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1 (Screening) and a stable dose of sulfonylurea for at least 8 weeks prior to the Screening visit~Exclusion criteria:~* Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)~* History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1~* Positive serological test for hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-cholesterol greater than or equal to 100 mg/dL at screening~* Men and nonpregnant, nonlactating women~* Use of stable lipid-modifying therapy for at least 4 weeks prior to screening that includes ezetimibe 10mg daily~Exclusion Criteria:~* Fasting blood triglycerides greater than or equal to 500 mg/dL~* Body Mass Index (BMI) greater than or equal to 50 kg/m2~* Recent history of clinically significant cardiovascular disease~* Use of statin therapy where doses are greater than those defined as low-dose within 4 weeks prior to screening; where low-dose is defined as an average daily dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bempedoic acid (Type: EXPERIMENTAL): bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
- placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 75 years~2. Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR)~3. Presence of excessive sweating by self-report~4. The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption~5. Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative~6. Excessive sweating has persisted for at least 4 weeks prior to baseline assessment~7. The excessive sweating is rated by the patient as at least moderately bothersome.~8. Episodes of excessive sweating occur at least twice a week for last 4 weeks~Exclusion Criteria:~1. Presence of another known disease that could potentially cause excessive sweating~2. Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past~3. Blood pressure less than 110 mm Hg systolic at the screening or baseline visits~4. Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).~5. Current antihypertensive treatment~6. History of significant cardiac disease, including coronary artery disease~7. Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)~8. History of priapism (persistent and painful erection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- terazosin (Type: EXPERIMENTAL): open-label treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prehospital Analgesia With Intra-Nasal Ketamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have an acute painful condition, as determined by the Emergency Health Services attendant~* A pain score of 5 or greater (signifying moderate or severe pain)~* Desire for analgesia when queried.~Exclusion Criteria:~* Less than 18 years of age.~* Previous hypersensitivity, intolerance or allergy to ketamine~* Chest pain~* Altered mental status~* Inability self-report pain score~* Pregnancy~* Nasal occlusion~* Systolic Blood Pressure \< 90 mm Hg~* Requiring immediate attention of the paramedic~* Ineligible to receive inhaled nitrous oxide as per BC EHS protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intranasal Ketamine (Type: EXPERIMENTAL): Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
- Placebo (Type: PLACEBO_COMPARATOR): Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 12 years old,~* had a history of SAR to ragweed pollen for at least one year~* had a positive skin test (prick) to short ragweed allergen.~* if female, had a negative urine pregnancy test (HCG) at the Screening Visit, and prior to treatment on the Treatment Visit~* were non pregnant women of childbearing potential and used a medically acceptable, adequate form of birth control.~Exclusion Criteria:~* developed signs or symptoms of bronchospasm, i.e., wheezing, dyspnea, and/or cough, during the priming sessions;~* had any significant medical condition which, in the judgment of the investigator, might interfere with the study or require treatment;~* had an upper respiratory or sinus infection within two weeks prior to treatment;~* had received escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for treatment of rhinitis;~* were female subjects who were pregnant, breast feeding, or premenarchal;~* could not adhere to concomitant medication prohibitions;~* had a known potential for hypersensitivity, allergy, or idiosyncratic reaction to mometasone furoate nasal spray;~* had asthma that requires systemic or inhaled corticosteroid treatment;~* had large nasal polyps, marked septum deviations, or any other nasal structural abnormality that significantly interferes with nasal airflow;~* had rhinitis medicamentosa;~* had any relevant abnormal vital sign due to an unknown underlying disease and considered by the investigator and Sponsor Monitor to contraindicate study participation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate Nasal Spray (Type: EXPERIMENTAL): None
- Placebo Nasal Spray (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of NDO, confirmed by urodynamics~* Practicing clean intermittent catheterization (CIC)~* Currently on treatment with an antimuscarinic drug~Exclusion Criteria:~* Known genitourinary condition (other than NDO) that may cause incontinence~* Bladder augmentation surgery~* Current Faecal impaction~* Electro-stimulation therapy within 2 weeks prior to screening and at any time during the study~* Subjects with the following gastro-intestinal problems: partial or complete obstruction, decreased motility like paralytic ileus, subjects at risk of gastric retention~* Reflux grade 3 or 4~* Current urinary tract infection (UTI)~* Subject has severe renal impairment (glomerular filtration rate \< 30 ml/min)~* Subject has severe hepatic impairment (Child-Pugh score \> 9).~* Subject has received intra-vesical botulinum toxin within 9 months prior to screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Solifenacin succinate (Type: EXPERIMENTAL): Participants aged 5 years to \< 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The NOR-SWITCH Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A clinical diagnosis of either rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease or chronic plaque psoriasis~2. Male or non-pregnant, non-nursing female~3. \>18 years of age at screening~4. Stable treatment with innovator infliximab (Remicade) during the last 6 months~5. Subject capable of understanding and signing an informed consent form~6. Provision of written informed consent~Exclusion Criteria:~1. Major co-morbidities, such as severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3 or 4) and/or severe respiratory diseases~2. Change of major co-medication during the last 2 months prior to randomization:~   RA, SpA and PsA: Initiation of systemic corticosteroids or synthetic DMARDs or other medication which according to the investigator would interfere with the stability of the disease.~   UC and CD: Initiation of systemic corticosteroids or an immunosuppressant or other medication which according to the investigator would interfere with the stability of the disease Psoriasis: Initiation of synthetic DMARDs or other medication which according to the investigator would interfere with the stability of the disease~3. Inadequate birth control, pregnancy, and/or breastfeeding~4. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible~5. Change in treatment with innovator infliximab (Remicade) during the last 6 months due to disease related factors, not including dose/frequency adjustments due to drug concentration measurements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: EXPERIMENTAL): Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
- INX (Type: ACTIVE_COMPARATOR): Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus for at least 12 months~* Current treatment with any basal bolus insulin for at least 12 months~* HbA1c below or equal to 10.0%~* BMI (Body Mass Index) below or equal to 35.0 kg/m\^2~* For the extension trial only: Completion of the 52 week treatment period in trial NN1250-3583 (NCT00982228)~Exclusion Criteria:~* Use of any other antidiabetic drug than insulin within the last 3 months~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Recurrent severe hypoglycemia or hypoglycemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven locally advanced adenocarcinoma of the prostate, defined as 1 of the following:~  * T3-4, N0 or NX, M0~ * T2, PSA greater than 40 µg/L~ * T2, PSA greater than 20 µg/L AND Gleason score at least 8~* Diagnosis made within the past 6 months~* Gleason score and PSA known~* Pelvic lymph nodes must be clinically negative~  * Lymph nodes no more than 1.5 cm in greatest diameter by CT scan or MRI of the pelvis~ * Negative needle aspirate required for any lymph node more than 1.5 cm~ * If a lymph node dissection was performed, it must be histologically negative~* No small cell or transitional cell carcinoma by biopsy~* No bony metastases by bone scan~PATIENT CHARACTERISTICS:~Age:~* Under 80~Performance status:~* ECOG 0-2~Life expectancy:~* At least 5 years excluding malignancy~Hematopoietic:~* Hemoglobin at least 10.0 g/dL~* WBC at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 2 times upper limit of normal (ULN)~* SGOT and SGPT less than 2 times ULN~* Alkaline phosphatase less than 2 times ULN~* No history of chronic liver disease~Renal:~* Creatinine less than 2 times ULN~Other:~* No contraindication to wide-field pelvic irradiation (e.g., inflammatory bowel disease or severe bladder irritability)~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Prior hormonal therapy within the past 12 weeks allowed provided the following conditions are met:~  * Negative bone scan before beginning any hormonal therapy~ * Extracapsular extension remains palpable on rectal re-exam~ * Baseline PSA known before beginning any hormonal therapy~* At least 4-6 weeks since prior 5-alpha-reductase inhibitor (e.g., finasteride) for benign prostatic hypertrophy~Radiotherapy:~* No prior pelvic irradiation~Surgery:~* No prior radical prostatectomy~* Prior transurethral resection of the prostate allowed~Other:~* No prior cytotoxic anticancer therapy~* No other prior treatment for prostate cancer~* No other concurrent anticancer therapy unless documented disease progression

- Gender: MALE
- Minimum Age: None
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Total Androgen Blockade (Type: ACTIVE_COMPARATOR): None
- Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete